Clinical2006
A single subcutaneous dose of CJC-1295 in healthy adults produced dose-dependent, prolonged elevation of GH and IGF-1 lasting several days, consistent with its long-acting DAC design.
Convenient weekly dosing
clinical
0 views
CJC-1295 with DAC
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) engineered for extended duration.
Overview
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) engineered for extended duration. The addition of DAC technology extends the half-life to 6-8 days, providing continuous growth hormone elevation rather than pulsatile release. This long-acting formulation offers convenience but differs significantly from natural GH secretion patterns.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
CJC-1295 with DACDrug Affinity ComplexDAC:GHRHLong-acting GHRH analogModified GHRH (1-29)
Status: Research compound - not FDA approved
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Growth hormone / IGF-1 modulationAnti-aging and body-composition researchGHRH analog pharmacology
Available Evidence
Human
A 2006 randomized, placebo-controlled study in healthy adults (Teichman et al., J Clin Endocrinol Metab, PMID 16352683) showed a single subcutaneous dose of CJC-1295 produced prolonged, dose-dependent increases in GH and IGF-1 secretion over several days.
Animal
Preclinical studies in rodents confirm sustained GH/IGF-1 elevation and biological activity of the DAC-conjugated GHRH analog; data are limited and mostly pharmacokinetic.
Uncertain
No long-term human safety or efficacy data exist for growth, body composition, or aging outcomes; the compound is not FDA-approved and is used almost exclusively as an unregulated research/bodybuilding peptide. Claims about 'pulsatile-like' GH patterns are speculative.
Key Studies & Findings
Benefits & Effects
sustained GH/IGF-1 elevation
clinical
significant body composition changes
clinical
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
Only one published controlled human pharmacokinetic study; no trials for clinical outcomes (body composition, aging, GH deficiency); no regulatory approval anywhere; long-term safety unknown.
Pharmacology
Injectable GHRH analog (modified GHRH 1-29) conjugated to a Drug Affinity Complex (DAC) that binds albumin, extending half-life to roughly 6-8 days versus minutes for native GHRH. The 2006 human study supports sustained GH/IGF-1 stimulation with weekly-dosing intent. Not FDA approved.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
1mg
Route: Injectable
Half-life: 6 days – 8 days
Research Protocols
Conservative Anti-Aging
- Dose
- 1mg
- Frequency
- Once weekly
- Route
- Subcutaneous
Standard Protocol
- Dose
- 2mg
- Frequency
- Once weekly
- Route
- Subcutaneous
Split Dosing
- Dose
- 1mg
- Frequency
- Twice weekly (Mon/Thu)
- Route
- Subcutaneous
Loading Protocol
- Dose
- 2mg first week, then 1mg
- Frequency
- Weekly
- Route
- Subcutaneous
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Why does DAC extend the half-life so dramatically?
The DAC moiety binds albumin, protecting the peptide from rapid enzymatic degradation and renal clearance, extending circulating half-life to about a week.
Is CJC-1295 with DAC approved for medical use?
No. It is not FDA-approved; the only published controlled human data are a single 2006 pharmacokinetic study.
Research Citations
1
Comparative Pharmacokinetics: DAC vs Non-DAC Variants (2015)
(2015)
2
Long-term Effects on GH/IGF-1 Axis (2012)
(2012)
3
Dose-Response Relationship of CJC-1295 DAC (2008)
(2008)
Related Resources
Quick Facts
Molecular Weight
3647.28
Mechanism
DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation
Safety Information
Higher side effect incidence than pulsatile protocols. Common: Water retention, joint pain, carpal tunnel symptoms. Monitor for signs of excessive GH: jaw growth, hand/feet enlargement. Not suitable for those with diabetes or cancer history. May worsen sleep apnea in predisposed individuals. Regular IGF-1 monitoring recommended for long-term use.
Citations
31.Comparative Pharmacokinetics: DAC vs Non-DAC Variants (2015)
(2015)
2.Long-term Effects on GH/IGF-1 Axis (2012)
(2012)
3.Dose-Response Relationship of CJC-1295 DAC (2008)
(2008)